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Background: Several observational studies have evaluated the effect of a single exposure window with blood
pressure (BP) medications on outcomes in incident dialysis patients, but whether BP medication prescription
patterns remain stable or a single exposure window design is adequate to evaluate effect on outcomes is unclear.
Methods: We described patterns of BP medication prescription over 6 months after dialysis initiation in
hemodialysis and peritoneal dialysis patients, stratified by cardiovascular comorbidity, diabetes, and other patient
characteristics. The cohort included 13,072 adult patients (12,159 hemodialysis, 913 peritoneal dialysis) who initiated
dialysis in Dialysis Clinic, Inc., facilities January 1, 2003-June 30, 2008, and remained on the original modality for at
least 6 months. We evaluated monthly patterns in BP medication prescription over 6 months and at 12 and
24 months after initiation.
Results: Prescription patterns varied by dialysis modality over the first 6 months; substantial proportions of patients
with prescriptions for beta-blockers, renin angiotensin system agents, and dihydropyridine calcium channel blockers
in month 6 no longer had prescriptions for these medications by month 24. Prescription of specific medication
classes varied by comorbidity, race/ethnicity, and age, but little by sex. The mean number of medications was 2.5 at
month 6 in hemodialysis and peritoneal dialysis cohorts.
Conclusions: This study evaluates BP medication patterns in both hemodialysis and peritoneal dialysis patients over
the first 6 months of dialysis. Our findings highlight the challenges of assessing comparative effectiveness of a
single BP medication class in dialysis patients. Longitudinal designs should be used to account for changes in BP
medication management over time, and designs that incorporate common combinations should be considered.
Keywords: Blood pressure medication, Dialysis, Medication use patternsBackground
The mortality rate for incident dialysis patients is high
in the first few months. A large proportion of these
deaths are due to cardiovascular causes, which remain
the leading causes of death after the first 6 months [1].
Hypertension, congestive heart failure (CHF), and
atherosclerotic heart disease occur in 85%, 32%, and
21%, respectively, of incident dialysis patients [1]. Two* Correspondence: wstpeter@cdrg.org
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reproduction in any medium, provided the ormeta-analyses of small randomized clinical trials in dia-
lysis patients receiving blood pressure (BP) medications
suggest that BP treatment decreased cardiovascular
events compared with control or placebo groups [2,3],
particularly among patients with hypertension [2]. How-
ever, heterogeneity among the trials was substantial, and
these analyses could not determine differential effects
among medications. Data from observational studies
suggest that exposure to specific medications (calcium
channel blockers, renin-angiotensin system [RAS]
agents, beta-blockers) is associated with reduced all-
cause or cardiovascular mortality compared with no BP
medication use [4-11]. However, clinical trials have beenl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cific agents because of small sample sizes and heterogen-
eity of study designs. Observational studies to date have
also been limited; some were conducted with prevalent
patients with varying dialysis duration and comorbid
conditions, possibly leading to problems with selection
bias and confounding by indication. These concerns can
be mitigated somewhat using incident populations. A
more concerning issue relates to evaluation of associa-
tions based on exposure at one point in time. Under-
standing utilization patterns of BP medications in the
months after dialysis initiation is imperative before ap-
propriate designs for future studies can be determined.
However, there is a paucity of data regarding patterns of
BP medication use in incident hemodialysis and peritoneal
dialysis patients. Despite extensive use, no data examine
longitudinal prescription patterns in the first few months
of dialysis. To date, data are limited to cross-sectional ana-
lyses of prevalent [1,7,11-15] or incident dialysis patients
[8,9,16]. In addition, these cross-sectional analyses have ei-
ther focused on hemodialysis patients or have grouped all
dialysis patients together, so very little information is avail-
able specifically regarding peritoneal dialysis patients. Of
the studies in incident patients, two use data from 1996–
1997 and do not reflect current practice patterns [8,9],
and one was a single small hospital study and is not
generalizable [16]. Changes in BP management over the
first few months of dialysis, when residual kidney function
may be present and volume status is changing, is also a
key consideration.
Thus, a thorough understanding of BP medication
prescription patterns among incident hemodialysis and
peritoneal dialysis patients, accounting for common car-
diovascular conditions that could influence prescription
patterns after dialysis initiation, is critical to inform
future comparative-effectiveness studies. We studied pre-
scription patterns of single and combination BP medica-
tions over the first 6 months of dialysis in hemodialysis
and peritoneal dialysis patients. We hypothesized that the
average number of BP medications per patient would
decrease, prescriptions by medication class would change
over the first 6 months, and prescription patterns would
vary by dialysis modality, sex, age, race, and cardiovascular
disease (CVD) or risk factors.
Methods
Overview
Our study was part of the broader Developing Evidence
to Inform Decisions about Effectiveness (DEcIDE)
Network Patient Outcomes in End-Stage Renal Disease
(DEcIDE-ESRD) Study funded by the Agency for Health-
care Research and Quality to examine the comparative
effectiveness of common treatment strategies in ESRD [17].
Cohorts were selected from patients treated in DialysisClinic, Inc., (DCI) facilities 2003–2008. DCI is a not-for-
profit medium-sized dialysis provider in the US with over
210 clinics in 27 states. DCI patient characteristics are simi-
lar to those of US dialysis patients in general, with an over-
representation of black patients [1]. We linked DCI data to
United States Renal Data System (USRDS) registry data to
obtain additional information.
We constructed hemodialysis and peritoneal dialysis
cohorts from all incident patients aged ≥ 18 years who
initiated treatment January 1, 2003-June 30, 2008, in a
DCI facility and were alive at 6 months, to examine BP
medication patterns in the 6 months after dialysis ini-
tiation. We excluded patients whose DCI start date
occurred more than 30 days after their USRDS start date
(obtained from the Medical Evidence Report, Centers for
Medicare & Medicaid [CMS] form CMS-2728), switched
modalities (hemodialysis to peritoneal dialysis or vice
versa, home hemodialysis, kidney transplant), transferred
to a non-DCI facility, withdrew from dialysis, or were
lost to follow-up during the first 6 months.
We determined presence of CVD, CHF, and diabetes
at dialysis initiation from information on form CMS-
2728 and over the first 6 months from Medicare claims
in USRDS data using International Classification of Dis-
eases Tenth Revision codes [17]. We determined oral BP
medication prescriptions from medication lists in the
DCI electronic medical record (EMR). This informa-
tional system maintains a history of all medications pre-
scribed to each DCI patient, allows physicians to write
prescriptions, and generates complete patient medica-
tion lists on care plans, physician encounter forms, and
transfer summaries when patients are hospitalized or
receive other outpatient care. The DCI EMR does not
interface with inpatient or other (non-dialysis) out-
patient clinic EMRs. Each month, patients bring in their
medication bottles and nurses verify, reconcile, and rec-
ord the medications to update the DCI EMR. BP medi-
cations are prescribed based on individual physician
discretion.
We assessed medication use in each month based on
drug start and stop dates in the EMR. We used the gen-
eric product identifier code to identify and classify each
medication into specific antihypertensive classes using
the Wolter’s Kluwer Medi-span® drug products database.
We quantified the percentage of patients surviving to
6 months who were prescribed beta-blockers, RAS
agents or dihydropyridine calcium channel blockers
(DHP-CCB), and further quantified the percentage of
surviving patients who continued to receive these classes
of medications at months 12 and 24. We also assessed
BP medication prescriptions in the most recent time-
frame available (2007–2008) to determine the most
current trends. Intravenous BP medications adminis-
tered during dialysis sessions were not included.
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We described the cohorts, numbers of BP medications,
and percentages of patients with prescriptions. We used
descriptive statistics (mean ± standard deviation [SD]) for
continuous variables (age, laboratory values) and percent-
ages for categorical variables. We stratified the hemo-
dialysis and peritoneal dialysis cohorts by modality, age,
race/ethnicity, sex, CHF, CVD (atherosclerotic heart dis-
ease, cerebrovascular accident/transient ischemic attack,
or peripheral vascular disease), and diabetes, as these vari-
ables have been shown to affect BP medication use [14].
We performed analyses using SAS version 9.2. We esti-
mated all percentages to a precision with 95% confidence
intervals of width ± 1.0% or less for hemodialysis and ±
3.3% or less for peritoneal dialysis patients.Figure 1 Flow diagram for patients included and excluded from the s
USRDS, United States Renal Data System; patients were evaluated for excluThe Johns Hopkins Medicine Institutional Review Board
(Baltimore, Maryland) reviewed and approved the study.Results
After applying inclusion and exclusion criteria, our study
cohorts consisted of 12,159 (93%) hemodialysis and 913
(7%) peritoneal dialysis patients, representing 62% of the
initial cohort (Figure 1). Peritoneal dialysis patients were
younger, less likely to be black, less likely to have ESRD
caused by diabetes or hypertension, less likely to have
cardiovascular conditions or diabetes, and more likely to
have ESRD caused by glomerulonephritis; they had
lower systolic BP and higher albumin and hemoglobin
(Table 1).tudy. DCI, Dialysis Clinic, Inc; HD, hemodialysis; PD, peritoneal dialysis;
sion criteria in the 6-month period after dialysis initiation.
St. Peter et al. BMC Nephrology 2013, 14:249 Page 4 of 11
http://www.biomedcentral.com/1471-2369/14/249Mean number of blood pressure medications and
prescription patterns, first 6 months
Most patients with any recorded medications in the
EMR were prescribed BP medications by 6 months after
dialysis initiation (Table 2). The mean (± SD) number
of prescribed medications was 2.8 ± 1.4 for peritoneal
dialysis and 2.3 ± 1.4 for hemodialysis patients in month 1,
but by month 6 the mean was 2.5 for both cohorts; thus
the mean over the first 6 months of dialysis increased for
hemodialysis and decreased for peritoneal dialysis patients.Table 1 Patient characteristics at baseline
All Hemodialysis Peritoneal
dialysis
n 13,072 12,159 913
Age, years 61.6 ± 15 62.0 ± 14.9 56.0 ± 14.5
Sex
Male 54.5 54.6 53.3
Female 45.5 45.5 46.7
Race
White 58.8 58.2 66.5
Black 36.1 37.4 28.0
Other 4.5 4.4 5.5
Hispanic 5.4 5.6 3.6
ESRD cause
Diabetes 48.1 48.5 43.4
Hypertension 27.3 27.7 21.7
Glomerulonephritis 9.5 9.0 16.9
Other 15.0 14.8 18.1
Cardiovascular risk factors or
disease
CHF 43.0 44.7 20.8
CVD 53.3 54.8 34.3
Diabetes 62.5 63.3 51.7
Other characteristics
Systolic blood pressure 147.7 ±
20.2
147.9 ± 20.2 144.3 ± 19.5
eGFR 9.8 ± 4.4 9.8 ± 4.4 9.8 ± 4.1
Body mass index 28.7 ±
7.6
28.8 ± 7.7 28.4 ± 6.4
Albumin (g/dL) 3.1 ± 0.7 3.1 ± 0.7 3.6 ± 0.6
Hemoglobin (g/dL) 10 ± 1.7 10.0 ± 1.7 10.8 ± 1.5
Calcium x phosphorus 49.9 ±
13.0
50.1 ± 13.0 47.8 ± 13.3
KT/V 1.5 ± 0.3 1.5 ± 0.3 1.6 ± 0.4
Note: Values are mean ± standard deviation or percentages. Age, eGFR,
albumin, body mass index, and hemoglobin were assessed at dialysis
initiation; blood pressure was the average value for each patient over month
1; calcium x phosphorus and KT/V were the average value for each patient
over months 4–6; cardiovascular risk factors or disease were assessed over the
first 6 months.
CHF, congestive heart failure; CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate; ESRD, end-stage renal disease.The percentage of peritoneal dialysis patients with no pre-
scribed BP medications increased from month 1 to month
6, and the percentage of hemodialysis patients decreased
slightly (Figure 2). Prescriptions for RAS agents increased
in both groups. Prescriptions for DHP-CCBs remained
stable for hemodialysis patients but declined for peritoneal
dialysis patients. Diuretics were prescribed for 48% of peri-
toneal dialysis and 29% of hemodialysis patients at month
1. Diuretic prescription declined in both groups over the
study timeframe. Central alpha 2 agonists (predominantly
clonidine) were prescribed for 19% of hemodialysis and
peritoneal dialysis patients in month 1; use of these agents
declined for peritoneal dialysis patients by month 6.
Minoxidil use was low in both groups. At month 6, the
most highly prescribed classes were any beta-blocker
(alpha-beta blockers such as carvedilol made up about
one-third), any RAS agent (angiotensin-converting en-
zyme inhibitors [ACEIs] were twice as common as angio-
tensin receptor blockers [ARBs]), DHP-CCBs, diuretics,
and central alpha 2 agonists.
Patterns by demographic group
Black patients were prescribed a higher mean (± SD) num-
ber of BP medications than white or other-race patients
(2.7 ± 1.4, 2.3 ± 1.3, 2.4 ± 1.3, respectively) at month 6.
Prescriptions of any beta-blocker and of alpha-beta
blockers were similar for black and white patients, but less
for Hispanics. Prescription of RAS agents was similar for
black and white peritoneal dialysis patients, but more fre-
quent (particularly ACEIs) for black and Hispanic than for
white hemodialysis patients. DHP-CCBs were less fre-
quently prescribed for white hemodialysis and peritoneal
dialysis patients than for other racial/ethnic groups, and
loop diuretics for black patients. Alpha blocker prescrip-
tions were similar for black and white patients, and central
alpha 2 agonists, hydralazine, and minoxidil were more
frequently prescribed for black than for white patients
across modalities. Prescription information for other race
and Hispanic ethnicity is provided for completeness, but
comparisons between modalities may not be accurate for
some medication classes due to few peritoneal dialysis
patients in these groups (Table 2).
In general, older patients were prescribed fewer BP medi-
cations than younger patients; means at 6 months were 2.7
± 1.4 for ages 18–44 years, 2.4 ± 1.3 for ages 65–74 years,
and 2.2 ± 1.3 for ages ≥ 75 years. For hemodialysis patients,
beta-blocker prescription was similar across age groups;
RAS agent, DHP-CCB, central alpha 2 agonist, and minoxi-
dil prescription declined monotonically as age increased,
and alpha-blocker prescription increased monotonically.
For peritoneal dialysis patients, beta-blocker prescription
increased monotonically as age increased (46% for ages
18–44 years, 61% for ages ≥ 75 years), and RAS agent
and DHP-CCB prescription varied across age groups.
Table 2 Percentages of incident hemodialysis and peritoneal dialysis patients with prescriptions for specific blood
pressure medications at 6 months, by race/ethnicity, 2003–2008
Hemodialysis, n =12,159 Peritoneal dialysis, n = 913
Medication All Black White Other Hispanic All Black White Other Hispanic
n 4543 7075 541 679 256 607 50 33
None 12 10 13 13 11 10 8 10 xx xx
Beta-blocker
Any 59 60 59 58 55 55 54 55 56 42
Alpha-beta 19 20 18 16 14 13 14 13 xx xx
Beta not alpha 41 40 41 42 41 42 40 42 44 30
RAS*
Any 45 49 43 48 51 52 52 53 38 48
ACEI 32 36 29 33 39 33 32 34 20 xx
ARB 17 18 17 18 16 23 23 22 26 xx
CCB
Any 49 57 43 49 55 50 55 37 50 45
DHP 40 48 34 43 48 40 48 35 48 39
Non-DHP 9 8 9 6 7 10 7 12 xx xx
Diuretic†
Any 28 23 31 29 33 41 32 45 42 45
Loop 26 21 29 26 32 38 31 42 36 42
Thiazide 5 4 5 5 5 9 6 10 xx xx
Alpha blocker 7 7 7 4 5 10 10 10 xx xx
Central alpha 2 agonist 19 27 15 12 19 15 21 14 xx xx
Hydralazine 8 10 7 5 9 4 6 3 xx xx
Minoxidil 4 6 3 3 2 2 5 2 xx xx
Note: Values are percentages except for the n row, which represents numbers of patients.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DHP, dihydropyridine; RAS, renin angiotensin
system agent.
*Renin-inhibitors comprised < 1% of RAS agents from 2003–2008.
†Potassium-sparing diuretics comprised < 1% of diuretic agents from 2003–2008.
xx represents less than 10 persons per cell; these percentages have been suppressed.
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Figure 2 Percentages of hemodialysis and peritoneal dialysis patients prescribed blood pressure medication classes or specific agents
over the first 6 months after dialysis initiation. BP, blood pressure; CCB, calcium channel blocker; Cent Alpha 2 Ag, central alpha 2 agonist;
DHP, dihydropyridine; diuretic, any including thiazides, thiazide-like, loop, potassium-sparing; HD, hemodialysis; NDHP, non-dihydropyridine; PD,
peritoneal dialysis; RAS, renin angiotensin system agent (angiotensin converting enzyme inhibitor or angiotensin receptor blocker).
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creased as age increased, but prescription of alpha blockers
increased (data not shown).
Male and female hemodialysis patients were prescribed
similar mean numbers of BP medications at month 6
(about 2.5), but female peritoneal dialysis patients re-
ceived fewer prescriptions than male patients (2.4 vs.
2.7). Alpha blockers were prescribed more commonly
for men (9% hemodialysis, 14% peritoneal dialysis) than
for women (4% across modalities). Beta-blockers were
prescribed more often for male than for female periton-
eal dialysis patients (60% vs. 49; data not shown).
Patterns by cardiovascular comorbidity and diabetes
BP medication prescription varied by cardiovascular co-
morbidity and cardiovascular risk factors. Any beta-
blocker, alpha-beta blockers, and loop diuretics were
more commonly prescribed for patients with CHF, CVD,
and diabetes across modalities than for patients withoutTable 3 Percentages of incident hemodialysis and peritoneal
pressure medications at 6 months by cardiovascular risk fact
Hemodialysis, n = 12,159
CHF CVD D
Medication All Yes No Yes No Yes
None 12 10 13 11 13 10
Beta-blocker
Any 59 65 55 64 53 62
Alpha-beta 19 26 13 22 15 20
Beta not alpha 41 39 42 43 38 42
RAS*
Any 45 45 45 44 46 49
ACEI 32 32 31 31 32 34
ARB 17 16 17 16 18 19
CCB
Any 49 44 52 45 52 49
DHP 40 36 43 37 43 41
Non-DHP 9 8 9 8 9 9
Diuretic†
Any 28 31 24 28 26 31
Loop 26 30 22 26 24 29
Thiazide 5 5 4 4 5 5
Alpha blocker 7 6 7 7 6 7
Central alpha 2 agonist 19 18 20 17 21 20
Hydralazine 8 11 6 9 7 9
Minoxidil 4 3 4 3 5 4
Note: Values are percentages except for the n row, which represents number of ind
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; C
system agent.
*Renin-inhibitors comprised < 1% of RAS agents from 2003–2008.
†Potassium-sparing diuretics comprised < 1% of diuretic agents from 2003–2008.these conditions. RAS agents were more commonly pre-
scribed for patients with than without diabetes across
modalities, but prescriptions were similar for patients
with and without CHF or CVD. DHP-CCBs were less
frequently prescribed for patients with CHF and CVD
than for patients without these conditions. Hydralazine
was more frequently prescribed for hemodialysis and
peritoneal dialysis patients with than without CHF
(Table 3).
Patterns in combination blood pressure medications
Combination BP medication prescriptions were com-
mon. Beta-blockers were the only single medication class
prescribed in ≥ 5% of patients. In the overall cohort, 43
BP medication class combinations were detected with
classes defined as any beta-blocker, any RAS agent,
DHP-CCBs, diuretics, central alpha 2 agonists, and
remaining categories “other”. Figure 3 shows the most
common combinations prescribed for hemodialysis anddialysis patients with prescriptions for specific blood
or or disease, 2003-2008
Peritoneal dialysis, n = 913
iabetes CHF CVD Diabetes
No All Yes No Yes No Yes No
15 10 7 10 7 11 5 14
54 55 69 51 67 48 61 48
16 13 25 10 17 11 16 10
38 42 44 41 51 37 45 38
39 52 54 51 55 50 57 46
27 33 36 32 34 32 35 30
14 23 22 23 25 22 26 19
47 50 43 51 48 51 54 44
39 40 35 41 38 41 42 37
8 10 8 10 10 10 13 7
21 41 55 37 52 35 50 32
19 38 53 34 50 33 47 29
3 9 13 8 13 6 12 5
7 10 8 10 12 9 11 7
18 15 14 16 14 16 16 14
7 4 9 3 5 4 6 3
5 2 2 3 1 3 2 2
ividuals.
CB, calcium channel blocker; DHP, dihydropyridine; RAS, renin angiotensin
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Figure 3 Blood pressure medications (single or in combination) prescribed for ≥ 5% of hemodialysis or peritoneal dialysis patients
with at least one blood pressure medication prescription. BB, beta blocker; BP, blood pressure; DHP, dihydropyridine; diuretic, any including
thiazides, thiazide-like, loop, potassium-sparing; RAS, renin angiotensin system agent (angiotensin converting enzyme inhibitor or angiotensin
receptor blocker).
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agents were overall the most frequently prescribed medi-
cations, when combinations were further collapsed to
beta-blockers, RAS agents, and other, regimens includ-
ing beta-blockers with and without RAS agents were the
most common (Figure 4).Continuing blood pressure medications after 6 months
We evaluated the percentage of patients who survived
and continued the same BP medication at 12 and
24 months as at 6 months. Of all patients prescribed a
beta-blocker at 6 months, 89% and 76% of those who
survived at 12 and 24 months, respectively, continued
beta-blocker prescriptions. In comparison, 79% and 59%Pe
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s
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Figure 4 Blood pressure medication combinations prescribed for ≥ 10
one blood pressure medication prescription. BB, beta blocker; BP, blood
converting enzyme inhibitor or angiotensin receptor blocker).continued DHP-CCB prescriptions and 83% and 66%
RAS agent prescriptions (data not shown).
Patterns for 2007–2008
We evaluated the percentages of patients prescribed
various BP medication classes and the most frequently
prescribed agents in those classes at 6 months in the
most current timeframe, 2007–2008, to evaluate trends
over time. Compared with the overall timeframe of
2003–2008, prescription of beta-blockers across modal-
ities and of ACEIs and loop diuretics in peritoneal dialy-
sis patients were more frequent in 2007–2008.
Percentages of patients prescribed ARBs, DHP-CCBs,
alpha blockers, and central 2 alpha agonists remained
stable (Table 4).Hemodialysis
Peritoneal dialysis
RAS (not BB) ±
any other
BP med
Any BP med
(not BB
or RAS)
% of hemodialysis or peritoneal dialysis patients with at least
pressure; RAS, renin angiotensin system agent (angiotensin
Table 4 Percentages of hemodialysis and peritoneal dialysis
patients prescribed specific blood pressure medications
within frequently prescribed classes,* 2007–2008
Hemodialysis
patients
Peritoneal
dialysis patients
Class and medication Class Agent Class Agent
Beta blockers 65.6 60.4
Metoprolol succinate 25.5 32.8
Metoprolol tartrate 27.7 25.8
Carvedilol (alpha-beta blocker) 24.7 22.7
Atenolol 11.0 7.8
Labetalol (alpha-beta blocker) 9.1 7.0
% of class represented 98.0 96.1
ACEIs 31.4 39.6
Lisinopril 66.6 60.7
Enalapril 9.7 1.2
Benazepril 9.5 16.7
Ramipril 4.6 7.1
Fosinopril 4.4 4.8
Quinapril 4.3 7.1
% of class represented 99.1 97.6
ARBs 17.0 23.1
Valsartan 40.4 36.7
Losartan 31.4 38.7
Irbesartan 11.0 8.2
Olmesartan 9.2 4.1
Telmisartan 5.3 8.2
Candesartan 2.7 4.1
% of class represented 100 100
DHP-CCBs 43.4 39.2
Amlodipine 66.2 61.4
Nifedipine 23.2 21.7
Felodipine 5.6 8.4
Nisoldipine 4.0 4.8
% of class represented 99.0 96.3
Loop diuretics 29.2 45.3
Furosemide 84.7 89.6
Bumetanide 10.4 6.3
Torsemide 4.9 4.2
% of class represented 100 100
Central alpha 2 agonist 19.5 12.3
Clonidine 98.9 96.2
Methyldopa 0.8 3.8
% of class represented 99.7 100
Alpha blockers 6.6 11.8
Doxazosin 63.5 68.0
Terazosin 33.8 32.0
Table 4 Percentages of hemodialysis and peritoneal dialysis
patients prescribed specific blood pressure medications
within frequently prescribed classes,* 2007–2008
(Continued)
Prazosin 2.7 0.0
% of class represented 100 100
Hydralazine 11.1 4.7
% of class represented 100 100
Note: Values are percentages.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor
blocker; DHP-CCB, dihydropyridine calcium channel blocker.
*Prescribed in at least 10% of hemodialysis or peritoneal dialysis patients at
month 6 after dialysis initiation.
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2007–2008 were metoprolol succinate (sustained re-
lease), metoprolol tartrate (non-sustained release), and
the alpha-beta blocker carvedilol. Lisinopril was the pre-
dominant ACEI prescribed, and losartan and valsartan
the predominant ARBs. Amlodipine was the predomin-
ant DHP-CCB prescribed and doxazosin the predomin-
ant alpha blocker. Furosemide was virtually the only
loop diuretic and clonidine the only central alpha 2
agonist prescribed.
Discussion
Our study describes BP medication use in the first
6 months after dialysis initiation in a large population of
hemodialysis and a smaller population of peritoneal dia-
lysis patients. In hemodialysis patients, beta-blocker
prescriptions increased over 6 months, DHP-CCB pre-
scriptions remained stable, and diuretic and hydralazine
prescriptions decreased slightly. In peritoneal dialysis pa-
tients, the percentage prescribed beta-blockers remained
stable over 6 months and prescriptions of diuretics,
DHP-CCBs, and central alpha 2 agonists steadily de-
creased. Prescription of RAS agents increased in both
cohorts. The mean number of prescribed medications
increased for hemodialysis but decreased for peritoneal
dialysis patients over 6 months. Although prescription
patterns appeared to stabilize in both cohorts by months
5 and 6, a substantial percentage of patients prescribed
specific medications at month 6 were no longer prescribed
those medications at month 24. Combination prescrip-
tions were common in both cohorts. We found trends
toward increased beta-blocker use in both cohorts and
ACEI and loop diuretic use in peritoneal dialysis patients
comparing 2003–2008 data with 2007–2008 data.
Our study has several strengths. First, data were ob-
tained from the third-largest dialysis provider in the US,
allowing us to evaluate differences in BP medication pre-
scriptions between hemodialysis and peritoneal dialysis
patients and to stratify our analyses by several character-
istics, including baseline CHF, CVD, and diabetes, which
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[14]. Second, our analysis provides in-depth examination
of contemporary prescribing patterns, which is import-
ant because BP medication prescription is influenced by
available evidence on efficacy and by generic availability.
Third, we evaluated use of combination prescriptions,
which was not reported in previous studies.
Our results reflect a purely descriptive analysis; results
have not been adjusted for important patient characteris-
tics. In addition, our study did not identify reasons for ap-
parent differences in prescription patterns by modality over
the first 6 months. Some of the apparent differences may
stem from differing baseline characteristics. For instance,
beta-blockers were prescribed for more hemodialysis than
peritoneal dialysis patients. Hemodialysis patients were older,
on average, and beta-blockers were more likely to be pre-
scribed for older patients. Hemodialysis patients had more
CHF, CVD, and diabetes, and beta-blockers were more likely
to be prescribed in patients with these conditions.
We hypothesized that the mean number of medications
would decrease over time as volume control improved.
However, the mean number of medications increased for
hemodialysis patients but decreased for peritoneal dialysis
patients over the first 6 months. Residual renal function
declines more rapidly with hemodialysis than with peri-
toneal dialysis [18,19], possibly necessitating additional
BP medications in hemodialysis patients over the first
6 months. For peritoneal dialysis patients, only prescrip-
tion of RAS agents increased, and prescription of all other
medications declined or remained stable (beta-blockers).
Perhaps maintained residual renal function with RAS
agents, along with better volume control, allowed for
reduced medications in peritoneal dialysis patients.
Our findings regarding BP medication patterns among
dialysis patients with CHF are consistent with Wetmore
et al., who found that CHF was associated with a 9%
increase in odds of beta-blocker use and no increase in
RAS agent use in dually eligible (Medicare/Medicaid)
prevalent hypertensive dialysis patients [14]. Our strati-
fied analysis also showed much higher use of any beta-
blocker in hemodialysis and peritoneal dialysis patients
with than without CHF, driven mainly by prescription of
beta-blockers with alpha activity. Similarly, we found
little difference in RAS agent use among patients with or
without CHF. Wetmore et al. also showed higher odds
of RAS agent use in prevalent dialysis patients with than
without diabetes [14], consistent with results from our
stratified analysis.
In month 1, 48% of peritoneal dialysis and 29% of
hemodialysis patients received diuretics, despite the
same estimated glomerular filtration rate at dialysis initi-
ation. However, diuretic use declined more rapidly over
6 months in peritoneal dialysis patients, which was un-
expected since decline in renal function is slower inthese patients [19]. Loop diuretics have not been shown
to preserve residual renal function [20], and an interest-
ing question relates to whether increased prescription of
RAS agents in peritoneal dialysis patients after dialysis
initiation led to decreased glomerular filtration rate or
improved BP enough to obviate need for diuretics in
some patients. One analysis of Dialysis Outcomes and
Practice Patterns Study (DOPPS) data showed that diur-
etic use increased in incident US hemodialysis patients
1997–2001 (23% to 30%), and use was associated with
lower interdialytic weight gain and lower odds of hyper-
kalemia [21]. Similarly, our 2007–2008 data showed
diuretic prescriptions for 29% of DCI hemodialysis pa-
tients at month 6.
Comparing BP medication prescription data in our inci-
dent cohort of DCI dialysis patients in 2007–2008 with a
large prevalent cohort of US dialysis patients enrolled in
Medicare Part D in 2007 (n = 158,702), we found similar
proportions prescribed beta-blockers (DCI: hemodialysis,
66%; peritoneal dialysis, 60% vs. USRDS: 64%), ARBs
(DCI: hemodialysis, 17%; peritoneal dialysis, 23% vs.
USRDS: 21%), and DHP-CCBs (DCI: hemodialysis, 43%;
peritoneal dialysis, 39% vs. USRDS: 46%), but much higher
proportions prescribed diuretics (DCI: hemodialysis, 29%;
peritoneal dialysis, 45% loop diuretics vs. USRDS: 17% any
diuretic), and lower proportions prescribed ACEIs (DCI:
hemodialysis, 31%; peritoneal dialysis 40% vs. USRDS:
38%) and central alpha 2 agonists (DCI: hemodialysis,
20%; peritoneal dialysis, 12% vs. USRDS: 23%) [15]. The
higher proportions prescribed diuretics in our cohorts pre-
sumably reflect higher residual renal function in the DCI
incident than in the USRDS prevalent population.
Several observational studies using incident cohorts
from Dialysis Morbidity and Mortality Wave 2 data have
evaluated the influence of single BP or cardioprotective
medications on long-term outcomes with exposure to
a BP medication at a single point [6,8-10]; based on
our findings, results may be confounded by substantial
changes in BP medication prescription patterns over the
first months of dialysis. We also found that a substantial
percentage of patients prescribed specific medications at
6 months were no longer prescribed those medications
at 24 months. This clearly requires further study. How-
ever, observational studies of BP medications in preva-
lent patients using a single exposure period and long
follow-up periods may also be confounded [11].
Our findings regarding distributions of use for specific
agents differed from those of a prior study of prevalent
dialysis patients [14]. Regarding beta-blockers, we found
higher use of metoprolol products and carvediol and
less of atenolol and labetalol. As metoprolol succinate (sus-
tained release) is now available in a generic version, one
would expect prescription patterns to shift toward higher
use if this study were repeated in a more contemporary
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duces left ventricular volume in dialysis patients with di-
lated cardiomyopathy [22]. Generic carvediol became
widely available in 2007, partially explaining its higher use
in our cohort.
Prescription of multiple BP medications was common
across modalities. Prescription patterns varied for each
agent and by modality in the first 6 months after dialysis
initiation. These patterns are important to consider in the
design of comparative-effectiveness studies of BP medica-
tions in dialysis patients. As prescription patterns differ
distinctly, hemodialysis and peritoneal dialysis patients
should not be grouped together in studies evaluating the
effect of medications on outcomes. On a population level,
prescription patterns varied by medication class in the first
6 months, but appeared to stabilize by months 5 and 6.
This suggests that a time-dependent approach should be
used in assessing medication effect in incident patients if
follow-up starts at dialysis initiation. Our evaluation of
changes over time in individual patients prescribed beta-
blockers, RAS agents, and/or DHP-CCBs at month 6
showed that time-dependent changes in prescriptions
should be considered even after 6 months, particularly if
follow-up time is longer than 6–12 months. Impact of and
possible interactions with other concurrent medications
should also be considered in designing future studies.
Our study has some limitations. Although characteris-
tics of our cohort were similar to national characteristics
[1], DCI medication prescribing patterns may not reflect
patterns in other dialysis facilities. Since data were de-
rived from EMRs, we know only that medications were
prescribed, not whether patients consumed them. Fur-
ther, accuracy of DCI outpatient medication lists may
vary by dialysis unit and may not correctly reflect recent
BP medication prescription changes made by nondialysis
health care providers. In addition, we required patients
to survive for 6 months in order to evaluate BP manage-
ment in a stable cohort; in analyses of BP medications at
12 and 24 months, we required patients to survive to
those points. Prescription patterns may differ for surviv-
ing patients and for patients who died. The number of
included peritoneal dialysis patients was relatively small,
which limited interpretation of results in some race and
ethnicity groups. Finally, although we stratified our find-
ings by important patient characteristics, our analyses
are largely descriptive and do not adjust for multiple
characteristics that could influence medication prescrip-
tion. Thus, the data from hemodialysis and peritoneal
dialysis patients are not directly comparable, because the
characteristics of these populations differ.
Conclusions
In conclusion, our study evaluates BP medication pre-
scription patterns in hemodialysis and peritoneal dialysispatients in the first 6 months after dialysis initiation. Ob-
servational studies attempting to compare medication ef-
fectiveness should account for the time-varying nature
of BP medication prescriptions, particularly in the first
6 months and if follow-up extends beyond 6–12 months.
Given that most patients are prescribed multiple medi-
cations, investigators should consider study designs that
incorporate medication combinations. Finally, prescrip-
tion patterns after dialysis initiation differ by modality,
and study designs should account for these differences.
Further research is necessary to determine the effects of
BP medication patterns on intermediate outcomes such
as BP variability, and key clinical outcomes such as car-
diovascular mortality and hospitalization, sudden cardiac
death, and quality of life.
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